New hope for aggressive brain tumors: experimental combo targets first recurrence
NCT ID NCT07431216
First seen Feb 25, 2026 · Last updated May 07, 2026 · Updated 6 times
Summary
This early-stage trial tests a new drug, STAR-001, combined with the old blood-pressure medicine spironolactone in about 68 adults whose glioblastoma (a fast-growing brain cancer) has come back after initial treatment. The goal is to see if the combination is safe and can shrink tumors. Participants receive STAR-001 by IV twice per 3-week cycle and take spironolactone pills before each infusion.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA (GBM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.